Jump to Main Content
Lenalidomide, an anti-tumor drug, regulates retinal endothelial cell function: Implication for treating ocular neovascular disorder
- Dong, Ling-Feng, Yao, Jin, Wang, Xiao-Qun, Shan, Kun, Yang, Hong, Yan, Biao, Jiang, Qin
- Biochemical and biophysical research communications 2015 v.465 pp. 678-684
- angiogenesis, anti-inflammatory activity, antineoplastic agents, cell movement, cell viability, diabetic retinopathy, endothelial cells, macular degeneration, premature birth, protein synthesis
- Ocular angiogenesis is an important pathologic character of several ocular diseases, such as retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration (AMD). Inhibition of ocular angiogenesis has great therapeutic value for treating these dieses. Here we show that lenalidomide, an anti-tumor drug, has great anti-angiogenic potential in ocular diseases. Lenalidomide inhibits retinal endothelial cell viability in normal and pathological condition, and inhibits VEGF-induced endothelial cell migration and tube formation in vitro. Moreover, lenalidomide inhibits ocular angiogenesis in vivo through the reduction of angiogenesis- and inflammation-related protein expression. Collectively, lenalidomide is a promising drug for treating ocular angiogenesis through its anti-proliferative and anti-inflammatory property.